Gregory Gordon

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Karine Clément, Erica L T van den Akker, Jesús Argente et al. · The Lancet Diabetes & Endocrinology · 2020 · 463 citations

Medicine, Endocrinology, Pharmacology +15

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in <scp>Bardet‐Biedl</scp> syndrome

Robert Haws, Sheila M. Brady, Elisabeth K. Davis et al. · Diabetes Obesity and Metabolism · 2020 · 128 citations · Full text

Agriculture, Pharmacology, Pharmacotherapy +17

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Jonathan W. Goldman, Robert N. Raju, Gregory Gordon et al. · BMC Cancer · 2013 · 116 citations · Full text

Medicine, Oncology, Pharmacology +15

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

Robert Haws, Gregory Gordon, Joan C. Han et al. · Contemporary Clinical Trials Communications · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Karine Clément, van den Akker E, Jesús Argente et al. · Yearbook of pediatric endocrinology · 2021 · 16 citations

Medicine, Endocrinology, Pharmacology +15